4SC AG: 4SC publishes Q1 2024 report
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
4SC AG (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients suffering with advanced-stage c…
Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cut…
4SC AG (4SC, FSE Prime Standard: VSC) today published its financial results for the financial year ended 31 December 202…
The Board of Management of 4SC AG (4SC, FSE Prime Standard: VSC) announced today that according to its best judgment, th…
4SC AG (4SC or "the Company") (4SC, FSE Prime Standard: VSC), a biotech company improving the lives of patients sufferin…
Positive topline data for resminostat in RESMAIN pivotal study demonstrating 97.6% improvement in progression free survi…
. Financial Highlights Direct MagnetOs sales increased by 148% from CHF 4.9 million to CHF 12.2 million, total revenue…
4SC AG (4SC, FSE Prime Standard: VSC) today published the financial results for the financial year ended 31 December 202…
Gesamtumsatz für das Geschäftsjahr 2022 in Höhe von 12,85 Milliarden US-Dollar – Wachstum von 9% im Vergleich zum Vorjah…
VMware, ein führender Anbieter von Unternehmenssoftware, gab heute die Finanzergebnisse für das dritte Quartal des Gesc…